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Abstract The first prospective fluorinated PET tracers for imaging hy-
poxia obtained via thiazolidine-ligation are reported. Three 1,2-thiol-
amine linkers were combined with four different 2-nitroimidazole spac-
ers via amide or urea bond formation. The resulting compounds were
submitted to thiazolidine-ring-forming ligation reaction with the fluori-
nated carbohydrate L-5-fluoro-5-deoxy-ribose (FDR), affording the de-
sired candidate PET tracers in variable yields. The same ligation reac-
tions performed on L-ribose – a by-product of [18F]FDR radiosynthesis –
under conditions mimicking a radiochemical production showed that
the fluorinated adducts can be efficiently purified and isolated by HPLC.
Finally, one of the prospective hypoxia tracers was successfully pro-
duced in radiolabelled form in 29.2% radiochemical yield from [18F]FDR.
Key words hypoxia, radiofluorination, thiazolidines, nitroimidazole,
bio-orthogonal ligation
Hypoxia occurs in cells and tissues when oxygen de-
mand exceeds supply.1,2 The irregular vasculature typical of
solid tumours does not sufficiently support cellular oxygen
demand, leading to the development and progression of
heterogeneous hypoxic cancer areas, which are generally
poorly responsive to chemo- and radio-therapies.3,4 Accu-
rate imaging of hypoxic regions could allow clinicians to
stratify patients and develop more efficient treatment
strategies to improve therapeutic outcomes.5,6 Identifica-
tion and quantification of hypoxic areas in tumours – and in
other pathologies – is therefore important for planning the
most appropriate and personalised therapeutic approach.7,8
Owing to its high sensitivity and non-invasive nature, PET
imaging is emerging as the method of choice for in vivo
identification, characterization and discrimination of hy-
poxic areas.6,9 In the last two decades, several PET tracers
for hypoxia have been described, but all of them are affect-
ed by significant drawbacks, such as low signal-to-noise ra-
tios, slow accumulation in hypoxic regions and poor brain
uptake, therefore the development of new hypoxia-targeted
PET tracers remains a very active area of research.10,11 L-5-
Fluoro-5-deoxy-ribose ([18F]FDR) 2 (Figure 1) has recently
emerged as a promising prosthetic group for rapid, indirect
radiolabelling of bioactive molecules via oxime bond for-
mation.12–15
As an alternative to the oxime bond, thiazolidine ring
formation could be used as a site-specific ligation method
via reaction of a 1,2-thiol-amine function with a carbonyl
group – including masked carbonyls of carbohydrates and
hemiacetals – in mildly acidic or basic conditions (pH 4 to
8).16–18 Importantly, the thiazolidine ring is generally stable
in a wide pH range (from 4 to 10), thus representing an at-
tractive linkage option. In order to further investigate the
efficiency of [18F]FDR as a radiolabelling agent and expand
the library of prospective PET tracers for hypoxia imaging,
we designed a novel class of candidate tracers [18F]1 (Figure
1) taking advantage of the last-step formation of a thia-
zolidine ring linkage between [18F]FDR 2 and terminal
2-amino-thiols 3 carrying a hypoxia-reactive 2-nitroimid-
azole group.
Figure 1  Novel hypoxia PET tracers via thiazolidine ligation with 
[18F]FDR
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M. Musolino et al. LetterSyn OpenThree different 2-aminoethanethiol linkers 4a–c
(Scheme 1) were selected to modulate the steric constraints
and lipophilicity of the final candidate tracers. The synthe-
sis was based on the conditions described by Duthaler et
al.19 A mixture of racemic cysteine 5 and conc. HCl in ace-
tone was heated at reflux for 6 h, affording the thiazolidine
intermediate 6. Samples of 6 were invariably found (by 1H
NMR spectroscopy) to contain 5–10% of cysteine hydro-
chloride 7. The mixture of 6 and 7 was allowed to react with
(Boc)2O in pyridine for 3 days to give the N-Boc-derivative
4a.19 NMR spectroscopy showed that this compound exists
as a mixture of rotamers, the signals of which did not show
coalescence at 60 °C either in CDCl3 or in CD3OD. Compound
4a was converted into the Weinreb amide 8 by reaction
with HATU and DIPEA, followed by addition of N,O-di-
methylhydroxylamine hydrochloride. Reduction of 8 using
LiAlH4 at 0 °C provided in good yield the aldehyde 9, which
was submitted to Wittig reaction with the phosphonium
ylide Ph3P=CHCO2Me to give exclusively the trans isomer of
the α,β-unsaturated ester 10.20 Hydrogenation reaction of
10 using H2 over Pd/C catalyst gave in quantitative yield the
saturated intermediate 11, which afforded the free carbox-
ylic acid 4b21 by basic hydrolysis of the ester function. The
carbinol 12 was obtained upon treatment of 11 with LiAlH4
at 0 °C, whereas the amine derivative 4c22 was obtained via
Mitsunobu reaction of phthalimide with 12 to give com-
pound 13, followed by phthalimide-ring cleavage with hy-
drazine monohydrate.
The 2-nitro-imidazole spacers 14a–d (Scheme 2 and
Scheme 3) were selected with the aim of introducing struc-
tural diversity within the series. The structure of the spacer
was expected to have an important effect on lipophilicity,
metabolic stability and ultimately on the imaging potential
of the candidate tracers 1.
Amines 14a,b were synthesised via Gabriel reaction
(Scheme 2) starting respectively from commercial 1,3-di-
bromopropane (15a) and 1,5-dibromopentane (15b). The
resulting phthalimides 16a,b23 were reacted with 2-nitro-
imidazole and K2CO3 in DMF upon heating to 115 °C to give
compounds 17a,b24 in good yields. The desired amines
14a,b were obtained by quantitative cleavage of the
phthalimido group with hydrazine monohydrate. The 1,2,3-
triazole-amine 14c was prepared via Huisgen cycloaddition
reaction between the azide 18, which was obtained by bro-
mine displacement reaction of 16a with sodium azide,25
and 1-propargyl-2-nitroimidazole 19, which was prepared
according to the literature,26 to afford phthalimide deriva-
tive 20. Removal of the phthalimido group with hydrazine
gave compound 14c in good overall yield.
Scheme 1  Synthesis of thiazolidine linkers 4a–c. Reagents and conditions: (a) acetone, conc. HCl, reflux, 6 h; (b) Boc2O, pyridine, N2 atm., r.t., 72 h; (c) 
N,O-Dimethylhydroxylamine hydrochloride, DIPEA, CH2Cl2, HATU, from 0 °C to r.t., 18 h; (d) LiAlH4, Et2O, N2 atm., 0 °C, 15 min; (e) Ph3P=CHCO2Me, THF, 
reflux, 18 h; (f) Pd/C 10wt. %, H2 atm., MeOH, r.t., 24 h; (g) LiAlH4, THF, N2 atm., 0 °C, 1 h; (h) Phthalimide, PPh3, diisopropyl azodicarboxylate (DIAD), 
THF, r.t., 16 h; (i) NH2NH2.H2O, reflux, 3 h; (j) LiOH, THF, r.t., 18 h.
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M. Musolino et al. LetterSyn OpenScheme 2  Synthesis of 2-nitroimidazole spacers 14a–c. Reagents and conditions: (a) Phthalimide, TEA, DMF, r.t., 48 h; (b) 2-Nitroimidazole, K2CO3, DMF, 
110–120 °C, 3–5 h; (c) NH2NH2·H2O, EtOH, 60–100 °C, 1–4 h; (d) NaN3, DMF, 120 °C, 4 h; (e) 1-Propargyl-2-nitroimidazole 19, CuSO4, sodium ascor-
bate, t-BuOH/H2O, r.t., 20 h.
2-Nitro-imidazolyl-acetic acid 14d27 (Scheme 3) was
prepared in four steps starting from 21, which provided
compound 22 after protection of the hydroxy group as tet-
rahydropyranyl acetal (THP) followed by introduction of the
2-nitroimidazole function in K2CO3 and DMF upon heating
to 115 °C. The resulting intermediate 23 was then dissolved
in a 6 M aq. HCl solution in MeOH to cleave the THP group,
followed by treatment of the resulting carbinol 24 with
Jones reagent (CrO3/H2SO4/acetone) in acetone to give the
desired compound 14d in 41% yield over the three steps.
Scheme 3  Synthesis of 2-nitroimidazole spacer 14d. Reagents and con-
ditions: (a) DHP, PPTS, CH2Cl2, r.t., 18 h; (b) 2-Nitroimidazole, K2CO3, 
DMF, 115 °C, 5 h; (c) 6 M HCl, MeOH, r.t., 18 h; (d) CrO3/H2SO4/acetone, 
r.t., 12 h.
Assembling of linkers 4a–c and spacers 14a–d to give
the tracers’ precursors 3a–f is shown in Scheme 4. Treat-
ment of carboxylic acid derivatives 4a–c with HATU and
DIPEA gave the corresponding activated esters, which were
reacted in situ with the amines 14a–d to afford the amides
25a–e.28 Different conditions were used to prepare the urea
derivative 25f.29 In this case, the amine 4c was added drop-
wise to a solution of carbonyldiimidazole (CDI) in CH2Cl2 at
0 °C to give the intermediate imidazocarboxyamide, which
gave the desired urea 25f upon in situ treatment with the
amine 14a.
The final unprotected 2-aminoethanethiol derivatives
3a–f30 (Scheme 4) were obtained by treatment of 25a–f
with a TFA/H2O/MeOH 3:2:1 mixture upon heating to 65 °C
for 2–4 h, followed by solvents removal under reduced pres-
sure at 60 °C. Then the crude compounds were dissolved in
ethanol (except compound 3c, which is only soluble in
aqueous solutions) and eluted through a SiliaBond® carbon-
ate pad (silica bound equivalent of tetramethylammonium
carbonate), which trapped residual TFA, acid by-products
and free-based 2-nitroimidazolium trifluoroacetate salts
formed during the thiazolidine hydrolysis.
In all cases, variable amounts of disulphide dimers were
obtained in mixture with the desired thiol monomers 3a–f,
as evidenced by both HPLC/MS analysis and NMR spectros-
copy. However, we did not attempt to purify further the
samples, as the disulphide dimers could be readily reduced
back to the monomeric thiols by treatment with 1,4-dithio-
threitol (DTT) before the following ligation reaction with
FDR 2 (Scheme 5).
The thiazolidine ring formation was performed by reac-
tion of 3a–f with cold [19F]FDR 2 using 1 M acetate buffer as
reaction medium in the presence of DTT. Acetate buffers
with different molarity (from 0.1 to 4.0) and pH (from 3 to
6) were tested at different temperatures (from r.t. to 50 °C)
in order to optimise the thiazolidine ring formation rate.
The optimised conditions were 2.5 equiv of 3a–f reacted
with 1 equiv of [19F]FDR(2) in the presence of 2.5 equiv of
DTT, using 1 M acetate buffer at pH 4.5 as reaction medium,
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M. Musolino et al. LetterSyn Openfor 20 min at 30 °C. The purification step was performed by
gradient RP-HPLC using a mixture of H2O/ACN + 0.05% (v/v)
of TFA as eluent. 1,2-Aminothiol derivatives 3a–f showed
markedly different reactivity towards [19F]FDR 2, showing
that the spacers’ structure plays an important role in the cy-
clisation reaction (see Table 1 for yields). Only the 1,2-thiol-
amine derivative 3c, incorporating a triazole ring, failed to
react under all the conditions explored, affording in very
low yields (<5%) the corresponding thiazolidine 1c, which
could not be isolated in pure form by RP-HPLC purification.
The radiosynthesis of [18F]FDR 2 is known to produce an
excess of L-ribose 26 as by-product,12 which, although less
reactive than 2, will compete with it in the thiazolidine ring
formation, affording the corresponding non-fluorinated thi-
azolidines 27a–f (Scheme 5) and decreasing the chemical
purity of the tracer.
Scheme 5  (a) 1 M acetate buffer CH3COOH/CH3COONa, pH 4.5, r.t., 20 min
Scheme 4  Synthesis of the 2-amino-thiol tracer precursors 3a–f. Reagents and conditions: (a) HATU, DIPEA, CH2Cl2, r.t., 18 h; (b) CDI, CH2Cl2, from 0 °C 
to r.t., 18 h; (c) TFA/H2O/MeOH 3:2:1, from r.t. to 65 °C, 2–4 h.
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M. Musolino et al. LetterSyn OpenTo simulate the radiosynthesis conditions, the thiazoli-
dine ring formation reaction was carried out in the pres-
ence of 10 equiv of 26 along with 1 equiv of [19F]FDR 2 and
1,2-aminothiol derivatives 3a–f. This experiment was per-
formed with the aim of assessing the formation of the de-
sired FDR thiazolidines in the presence of L-ribose 26 and
the possibility of performing an HPLC purification for sepa-
rating the [18F]FDR-derived tracers 1a–f from the non-ra-
dioactive L-ribose-derived thiazolidines 27a–f. As shown in
Table 1, as well as in the HPLC profiles (see the Supporting
Information), the retention times of the target FDR-thiazoli-
dines 1a–f are indeed significantly different to those of the
ribose-derived thiazolidines 27a–f.
Therefore, the final cold tracers [19F]1a–f could be iso-
lated and characterised by LC-MS. Their Log P values were
determined by RP-HPLC (isocratic phase H2O/EtOH 90:10).
Considering that the gold standard hypoxia tracer [18F]FMI-
SO has a Log P = 0.42, candidate tracers 1 appear to have
suitable lipophilicity for use in vivo. Thiazolidines 1a–f pre-
sented very complex NMR spectra owing to the presence of
four diastereomers, originated by the two (R/S) thiazolidine
stereogenic centres, plus different rotamers and trifluoro-
acetate salts. Only compound 1a31 was isolated in sufficient
quantity for being satisfactorily characterised by NMR spec-
troscopy, after treatment with SiliaBond® carbonate in or-
der to freebase the trifluoroacetate salts.
Radiolabelling tests for producing [18F]1a32 were con-
ducted on the 1,2-aminothiol derivative 3a, which was
treated with [18F]FDR (2)12,13 using a sodium acetate buffer
solution (Scheme 6). Also in this case, different reaction
conditions were tested with the aim of achieving the maxi-
mum radiochemical conversion within 40 minutes (see Ta-
ble 1S, Supporting Information).
Scheme 6  Radiosynthesis of [18F]1a. Reagents and conditions: (a) 6 M 
acetate buffer, pH 4.5, r.t., 30 min.
Eventually, we found that the use of a 6 M acetate buffer
solution (70% v/v concentration) in the reaction mixture
containing [18F]FDR (2), 3a and DTT (1:1) (in the range 2–4
M) at pH 4.5, provided the highest RCY (29.2%, decay cor-
rected). No further improvements could be achieved by
changing buffer concentration, pH or extending further the
reaction time.
The tracer identity was confirmed by superimposition
of the UV-HPLC profile of the cold reference [19F]1a with the
semi-preparative RP-HPLC radio-chromatogram of [18F]1a,
acquired before purification of the radiotracer (Figure 2).
In conclusion, we have designed and synthesised the
first candidate PET tracers (1) for hypoxia imaging based on
the use of [18F]FDR 2 as radiolabelling agent. The synthesis
is based on the formation of a thiazolidine-ring-linkage be-
tween [18F]FDR 2 and 1,2-thiol-amines 3, which occurs
with moderate to good efficiency depending on the struc-
ture of spacer and linker featured in 3. The method was suc-
cessfully tested for the radiosynthesis of [18F]1a, which was
produced in 29.2% radiochemical yield and successfully pu-
rified by RP-HPLC.
Table 1  Synthesis of Cold Tracers [19F]1a–f
Compound X Y Yield (%) tR–F (min) tR–OH (min)a log P (±SED)
1a CO NH(CH2)2 61.3 12.5 8.3 0.33 (±0.04)
1b CO NH(CH2)4 67.9 27.3, 28.4 20.0 0.64 (±0.04)
1d (CH2)2CO NH(CH2)2 11.2 22.4–23.4 20.3 0.68 (±0.04)
1e (CH2)3NH CO 31.8 15.6–18.4 10.0–11.5 0.26 (±0.04)
1f (CH2)3NH CONH(CH2)3 42.3 27.7–29.4 22.0–23.5 0.50 (±0.02)
a Retention time of the corresponding L-ribose analogue 26.
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275.2 [M+H]+, 297.2 [M+Na]+, 303.1 [M+K]+
(23) Böhmer, V.; Dozol, J.-F.; Grüttner, C.; Liger, K.; Matthews, S. E.;
Rudershausen, S.; Saadioui, M.; Wang, P. Org. Biomol. Chem.
2004, 2, 2327.
(24) Hay, M. P.; Wilson, W. R.; Moselen, J. W.; Palmer, B. D.; Denny,
W. A. J. Med. Chem. 1994, 37, 381.
(25) Ebran, J.-P.; Dendane, N.; Melnyk, O. Org. Lett. 2011, 13, 4336.
(26) Bejot, R.; Carroll, L.; Bhakoo, K.; Declerck, J.; Gouverneur, V.
Bioorg. Med. Chem. 2012, 20, 324.
(27) A shorter synthesis of 14d has been reported, see: Joyard Y.,
Azzouz R., Bischoff L., Papamicaël C., Labar D., Bol A., Bol V., Vera
P., Grégoire V., Levacher V., Bohn P.; Bioorg. Med. Chem.; 2013,
Figure 2  In black: semi-prep RP-HPLC Radio-analysis of radiotracer 
[18F]1a formation using 70% v/v of a 6 M acetate buffer solution in the 
aqueous solution of [18F]FDR (2). In red: superimposed UV chromato-
gram of the cold reference [19F]1a obtained using the same RP-HPLC 
conditions.Georg Thieme Verlag  Stuttgart · New York — SynOpen 2017, 1, 173–179
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M. Musolino et al. LetterSyn Open21: 3680; and references therein. However, imidazolyl carbinol
24 was already being used in our labs for a related project,
therefore it was used as an intermediate for 14d
(28) Synthesis of 25a: DIPEA (156 μL, 0.92 mmol) and HATU (350
mg, 0.92 mmol) were added to a solution of 4a (200 mg, 0.77
mmol) in anhydrous CH2Cl2 (10 mL) at 0 °C and the mixture was
allowed to react at r.t. for 1 h. Then the amino derivative 14a
(260 mg, 1.53 mmol) dissolved in CH2Cl2 (2 mL) was added to
the mixture. After 16 h under stirring, the mixture was washed
with a 0.5 M aq. NaOH solution (3 × 6 mL) and then with a 0.1 M
aq. HCl solution (3 × 6 mL), dried over Na2SO4 and concentrated
under reduced pressure. The crude material was purified by
flash chromatography (Hex/EtOAc, from 8:2 to 7:3) to afford
25a (229 mg, 72.3%) as a yellow oil. 1H NMR (CDCl3, 400 MHz,
mixture of rotamers): δ = 7.32 (s, 1 H), 7.08 (s, 1 H), 6.55 (br, 1
H), 4.72 (br, 1 H), 3.42–3.11 (m, 4 H), 1.82 (s, 3 H), 1.73 (s, 3 H),
1.42 (s, 9 H). 13C NMR (CDCl3, 100 MHz): δ = 171.7, 153.3, 144.7,
128.4, 127.0, 81.8, 71.4, 67.5, 47.4, 36.0, 31.0, 29.3, 28.9, 28.4
(3C). MS (ESI): m/z calcd for C17H27N5O5S: 436.2 [M+Na]+, 452.0
[M+K]+; found: 436.1 [M+Na]+, 452.0 [M+K]+
(29) Synthesis of 25f: A solution of 4c (152 mg, 0.56 mmol) in
CH2Cl2 (2 mL) was added dropwise to a solution of CDI (90 mg,
0.56 mmol) in anhydrous CH2Cl2 (3 mL), at 0 °C under N2 atmo-
sphere, then the mixture was allowed to react at r.t. for 1 h.
After 16 h under stirring, the mixture was added via syringe to a
solution of 14a (226 mg, 1.33 mmol) in CH2Cl2 (3 mL) under N2
atmosphere. After 16 h under stirring the mixture was concen-
trated under recued pressure. Purification by FC on silica gel
(Hex/EtOAc, from 3:7 to 7:3) gave 25f (148 mg, 56.7%) as a
yellow oil. 1H NMR (CDCl3, 400 MHz, 2 rotamers): δ = 7.35 (br, 1
H), 7.02 (br, 1 H), 5.55 (br, 2 H), 4.40 (t, J = 6.9 Hz, 2 H), 4.19 (br,
1 H), 3.24–2.94 (m, 5 H), 2.49 (d, J = 11.8 Hz, 1 H), 2.05–1.86 (m,
2 H), 1.81–1.66 (m, 2 H), 1.63 (s, 3 H), 1.61 (s, 3 H), 1.48–1.26
(m, 11 H). 13C NMR (CDCl3, 100 MHz, 2 rotamers): δ = 159.0,
152.7, 144.6, 128.2, 127.1, 80.3, 69.4, 64.0, 47.8, 39.8, 36.6, 31.6,
31.4, 30.6, 30.1, 29.6, 28.4 (3C), 27.3. MS (ESI): m/z calcd for
C20H34N6O5S: 471.2 [M+H]+, 493.2 [M+Na]+; found: 471.2
[M+H]+, 493.2 [M+Na]+
(30) Synthesis of 3a: Compound 25a was dissolved in a
TFA/H2O/MeOH 3:2:1 mixture and heated to 65 °C for 2 h. Sol-
vents were then concentrated under reduced pressure at 60 °C,
then the residue was dissolved in ethanol and passed through a
SiliaBond® carbonate pad to give the crude 3a as trifluoroacetate
salt (55.7 mg, 74.8%). The compound was used in the next reac-
tion without any further purification. 1H NMR (CD3OD, 400
MHz, in mixture with the dimer): δ = 7.62–7.54 (m, 1 H), 7.20–
7.15 (m, 1 H), 4.60–4.42 (m, 2 H), 4.31–4.19 (m, 1 H), 3.52–3.33
(m, 2 H), 3.24–3.09 (m, 2 H), 2.19–2.00 (m, 2 H). 13C NMR
(CD3OD, 100 MHz, in mixture with the dimer): δ = 167.4, 144.6,
127.4, 127.2, 51.7, 47.4, 37.8, 36.3, 29.7. MS (ESI): m/z calcd for
C9H15N5O3S: 274.1 [M+H]+, 296.1 [M+Na]+; found: 274.0 [M+H]+,
296.0 [M+Na]+
(31) Synthesis of 1a: [19F]FDR ([19F]2) (5 mg, 0.033 mmol) was
added to a solution of 3a (32.0 mg, 0.083 mmol) and DTT (12.8
mg, 0.083 mmol) in a 1 M sodium acetate buffer solution (pH
4.5), then the mixture was allowed to react at 30 °C for 20 min.
Purification by RP-HPLC (Column: Phenomenex Luna C18 250 ×
10.00 mm, 5 μm; mobile phase: A (H2O + 0.05% TFA), B (ACN +
0.05% TFA); gradient: from 5% B to 6% B in 15 min; flow: 5 mL
min−1; tR: 12.5 min) gave 1a as trifluoroacetate salt (10.6 mg,
61.3 %). NMR analyses were performed after treatment of 1a
with SiliaBond® carbonate (10% w/w) in EtOH, under gentle stir-
ring for 1 h in order to freebase trifluoroacetate salt. 1H NMR
(CD3OD, 400 MHz, – four diastereoisomers – two major isomer
in ~3:2 ratio were identified): δ = 7.55 (d, J = 1.2 Hz, 1 H), 7.16
(d, J = 1.2 Hz, 1 H), 4.89–4.83 (m, 1 H), 4.62–4.42 (m, 4 H), 4.25
(dd, J = 7.0, 6.8 Hz, 1 H), 4.09–4.04 (m, 1 H), 3.91 (dd, J = 7.4, 4.6
Hz, 1 H), 3.66 (dd, J = 7.4, 5.8 Hz, 1 H), 3.39–3.23 (m, 3 H), 3.02–
2.91 (m, 1 H), 2.16–2.05 (m, 2 H); δ (second isomer) = 7.57 (d,
J = 1.2 Hz, 1 H), 7.17 (d, J = 1.2 Hz, 1 H), 4.92 (d, J = 2.6 Hz, 1 H),
4.67 (dd, J = 9.8, 3.0 Hz, 1 H), 4.63–4.42 (m, 3 H), 4.25 (dd, J = 7.0,
6.8 Hz, 1 H), 4.04–3.95 (m, 1 H), 3.85–3.75 (m, 2 H), 3.39–3.14
(m, 3 H), 3.02–2.91 (m, 1 H), 2.16–2.05 (m, 2 H). 13C NMR
(CD3OD, 100 MHz, – four diastereoisomers – two major isomers
in ~3:2 ratio were identified): δ (first isomer) = 172.5, 144.7,
127.2, 127.1, 84.1 (d, JCF = 167 Hz), 73.6 (d, JCF = 7 Hz), 72.3, 72.1,
71.8 (d, JCF = 18 Hz), 71.4, 65.8, 35.8, 34.9, 30.0; δ (second
isomer) = 172.4, 144.7, 127.2, 127.1, 84.3 (d, JCF = 167 Hz), 73.6
(d, JCF = 7 Hz), 72.3, 72.0, 71.9, 71.9 (d, JCF = 18 Hz), 70.2, 66.2,
36.6, 34.9. 29.9. 19F NMR (376 MHz, CD3OD): δ (first isomer) =
–233.0 (dt, J = 48.0, 22.7 Hz); δ (second isomer) = –233.6 (dt, J1 =
48.0 Hz, J2 = 22.3 Hz); MS (ESI): m/z calcd for: C14H22FN5O6S:
408.1 [M+H]+, 430.1 [M+Na]+; found: 408.0 [M+H]+, 430.0
[M+Na]+
(32) Optimised radiosynthesis of [18F]1a: A solution of sodium
acetate buffer (6 M, pH 4.5) was added to a solution of 3a (2.5
mg, 6.4 μmol), DTT (1 mg, 6.4 μmol) and [18F]FDR ([18F]2) (2.5–
10 MBq) in 0.5–1.0 mL of H2O to form a 70% v/v sodium acetate
buffer solution (final concentration 4.2 M). After ~20 min the
mixture was purified by RP-HPLC (Column: Phenomenex Luna
C18 250 × 10.00 mm, 5 μm) to give [18F]1a in 29% RCY (decay
corrected)Georg Thieme Verlag  Stuttgart · New York — SynOpen 2017, 1, 173–179
